Trinity Biotech (TRIB) Competitors $0.92 +0.03 (+2.90%) Closing price 08/8/2025 03:59 PM EasternExtended Trading$0.93 +0.02 (+1.79%) As of 08/8/2025 07:21 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisChartCompetitorsEarningsHeadlinesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock TRIB vs. KLRS, PDSB, CVM, ANVS, OSTX, ADVM, KALA, PRLD, ABVC, and VTVTShould you be buying Trinity Biotech stock or one of its competitors? The main competitors of Trinity Biotech include Kalaris Therapeutics (KLRS), PDS Biotechnology (PDSB), CEL-SCI (CVM), Annovis Bio (ANVS), OS Therapies (OSTX), Adverum Biotechnologies (ADVM), KALA BIO (KALA), Prelude Therapeutics (PRLD), ABVC BioPharma (ABVC), and vTv Therapeutics (VTVT). These companies are all part of the "pharmaceutical products" industry. Trinity Biotech vs. Its Competitors Kalaris Therapeutics PDS Biotechnology CEL-SCI Annovis Bio OS Therapies Adverum Biotechnologies KALA BIO Prelude Therapeutics ABVC BioPharma vTv Therapeutics Trinity Biotech (NASDAQ:TRIB) and Kalaris Therapeutics (NASDAQ:KLRS) are both small-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their valuation, institutional ownership, earnings, media sentiment, risk, profitability, analyst recommendations and dividends. Do analysts rate TRIB or KLRS? Kalaris Therapeutics has a consensus price target of $3.00, indicating a potential upside of 12.36%. Given Kalaris Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Kalaris Therapeutics is more favorable than Trinity Biotech.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Trinity Biotech 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00Kalaris Therapeutics 0 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 2.00 Does the media prefer TRIB or KLRS? In the previous week, Trinity Biotech had 1 more articles in the media than Kalaris Therapeutics. MarketBeat recorded 1 mentions for Trinity Biotech and 0 mentions for Kalaris Therapeutics. Trinity Biotech's average media sentiment score of 0.00 equaled Kalaris Therapeutics'average media sentiment score. Company Overall Sentiment Trinity Biotech Neutral Kalaris Therapeutics Neutral Is TRIB or KLRS more profitable? Kalaris Therapeutics has a net margin of 0.00% compared to Trinity Biotech's net margin of -68.48%. Trinity Biotech's return on equity of 0.00% beat Kalaris Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Trinity Biotech-68.48% N/A -32.33% Kalaris Therapeutics N/A -62.08%-54.69% Which has higher earnings and valuation, TRIB or KLRS? Trinity Biotech has higher revenue and earnings than Kalaris Therapeutics. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioTrinity Biotech$61.56M0.27-$31.79M-$2.93-0.31Kalaris TherapeuticsN/AN/A-$58.77MN/AN/A Which has more risk & volatility, TRIB or KLRS? Trinity Biotech has a beta of 0.77, meaning that its share price is 23% less volatile than the S&P 500. Comparatively, Kalaris Therapeutics has a beta of 0.49, meaning that its share price is 51% less volatile than the S&P 500. Do insiders & institutionals have more ownership in TRIB or KLRS? 79.0% of Trinity Biotech shares are owned by institutional investors. Comparatively, 66.1% of Kalaris Therapeutics shares are owned by institutional investors. 8.2% of Trinity Biotech shares are owned by insiders. Comparatively, 75.0% of Kalaris Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term. SummaryTrinity Biotech beats Kalaris Therapeutics on 7 of the 11 factors compared between the two stocks. Get Trinity Biotech News Delivered to You Automatically Sign up to receive the latest news and ratings for TRIB and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding TRIB and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart TRIB vs. The Competition Export to ExcelMetricTrinity BiotechMED PRODUCTS IndustryMedical SectorNASDAQ ExchangeMarket Cap$16.57M$10.65B$5.50B$9.72BDividend YieldN/A2.00%4.59%4.12%P/E Ratio-0.3120.6130.0524.70Price / Sales0.2721.88456.53100.55Price / CashN/A23.6424.8428.01Price / Book-0.473.258.525.76Net Income-$31.79M$211.77M$3.27B$267.05M7 Day Performance30.25%3.02%6.13%5.08%1 Month Performance17.94%0.35%0.07%0.61%1 Year Performance-64.57%-9.81%36.43%22.83% Trinity Biotech Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)TRIBTrinity Biotech0.9433 of 5 stars$0.92+2.9%N/A-64.6%$16.57M$61.56M-0.31480News CoverageUpcoming EarningsKLRSKalaris TherapeuticsN/A$2.58-4.1%$3.00+16.3%N/A$50.31MN/A0.00110PDSBPDS Biotechnology1.4632 of 5 stars$1.12+2.8%$9.00+703.6%-63.5%$49.82MN/A-1.1920Upcoming EarningsCVMCEL-SCI0.9192 of 5 stars$9.25-2.1%N/A-79.5%$49.22MN/A-19.2743Positive NewsANVSAnnovis Bio1.7418 of 5 stars$2.68+6.8%$18.00+571.6%-66.8%$48.91MN/A-1.243News CoverageUpcoming EarningsOSTXOS Therapies2.4288 of 5 stars$1.73-1.1%$18.00+940.5%-59.0%$48.61MN/A-2.01N/ANews CoverageAnalyst ForecastADVMAdverum Biotechnologies4.0409 of 5 stars$2.51+8.2%$23.80+848.2%-65.1%$48.47M$1M-0.39190News CoverageUpcoming EarningsKALAKALA BIO3.7824 of 5 stars$7.45-0.7%$13.00+74.5%+26.2%$48.39M$3.89M-0.9030News CoverageEarnings ReportAnalyst DowngradePRLDPrelude Therapeutics2.749 of 5 stars$0.85+2.1%$4.50+432.0%-83.2%$46.77M$7M-0.50120News CoverageUpcoming EarningsABVCABVC BioPharma0.9088 of 5 stars$3.20+16.4%N/A+291.9%$46.70M$510K-24.6230News CoverageUpcoming EarningsVTVTvTv Therapeutics1.8566 of 5 stars$14.48-0.6%$35.50+145.2%+6.5%$46.56M$1.02M-4.819News CoverageUpcoming Earnings Related Companies and Tools Related Companies Kalaris Therapeutics Competitors PDS Biotechnology Competitors CEL-SCI Competitors Annovis Bio Competitors OS Therapies Competitors Adverum Biotechnologies Competitors KALA BIO Competitors Prelude Therapeutics Competitors ABVC BioPharma Competitors vTv Therapeutics Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:TRIB) was last updated on 8/10/2025 by MarketBeat.com Staff From Our Partners#1 Pre-IPO Opportunity For 2025 [Take Action Now!]James Altucher has scored 37X and even 60X returns on past pre-IPO deals. But now he says a much bigger opport...Paradigm Press | SponsoredGENIUS Act: Cancel Your Money?A new law called the GENIUS Act could quietly trigger the most radical shift in American finance in decades. B...Priority Gold | SponsoredBuffett’s $325 Billion Cash Problem — Solved by Gold?A bombshell announcement is just weeks away — and it could send shockwaves through the gold market. Most inves...Golden Portfolio | SponsoredMarket Crash Warning: How to Protect Your Wealth Before August 12thChina tariffs hit August 12—and experts warn a market meltdown may follow. A free guide from American Alter...American Alternative | SponsoredHe Called Nvidia at $1.10. Now, He Says THIS Stock Will…The original Magnificent Seven returned 16,894%—turning $7K into $1.18 million. Now, the man who called Nvi...The Oxford Club | SponsoredI trusted Trump and got screwedPorter Stansberry says he got one thing wrong—and now millions of Americans could pay the price. After warning...Porter & Company | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredThe stealth altcoin the financial world is underestimatingThe Single Most Undervalued DeFi Protocol You've Never Heard Of If there's one cryptocurrency you should b...Crypto 101 Media | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Trinity Biotech PLC Please log in to your account or sign up in order to add this asset to your watchlist. Share Trinity Biotech With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free TRIB Stock Alerts